Complete biosynthetic pathway to the antidiabetic drug acarbose.
Complete biosynthetic pathway to the antidiabetic drug acarbose.
复制标题
DOI:
10.1038/s41467-022-31232-4
复制
发表时间:
2022-06-15
影响因子:
16.6
通讯作者:
中科院分区:
文献类型:
--
作者:
Acarbose is a bacterial-derived α-glucosidase inhibitor clinically used to treat patients with type 2 diabetes. As type 2 diabetes is on the rise worldwide, the market demand for acarbose has also increased. Despite its significant therapeutic importance, how it is made in nature is not completely understood. Here, we report the complete biosynthetic pathway to acarbose and its structural components, GDP-valienol and O-4-amino-(4,6-dideoxy-α-D-glucopyranosyl)-(1→4)-O-α-D-glucopyranosyl-(1→4)-D-glucopyranose. GDP-valienol is derived from valienol 7-phosphate, catalyzed by three cyclitol modifying enzymes, whereas O-4-amino-(4,6-dideoxy-α-D-glucopyranosyl)-(1→4)-O-α-D-glucopyranosyl-(1→4)-D-glucopyranose is produced from dTDP-4-amino-4,6-dideoxy-D-glucose and maltose by the glycosyltransferase AcbI. The final assembly process is catalyzed by a pseudoglycosyltransferase enzyme, AcbS, which is a homologue of AcbI but catalyzes the formation of a non-glycosidic C-N bond. This study clarifies all previously unknown steps in acarbose biosynthesis and establishes a complete pathway to this high value pharmaceutical. The market demand for acarbose, a drug used for treatment of patients affected by type-2 diabetes, has increased. In this article, the authors report the acarbose complete biosynthetic pathway, clarifying previously unknown steps and identifying a pseudoglycosyltransferase enzyme, AcbS, a homologue of AcbI that catalyzes the formation of a non-glycosidic C-N bond.
登录
查看更多内容
影响因子:
5.1
作者:
Flatt PM;Wu X;Perry S;Mahmud T
通讯作者:
Mahmud T
影响因子:
16.6
作者:
通讯作者:
--
影响因子:
6.6
作者:
Mahmud, T;Lee, S;Floss, HG
通讯作者:
Floss, HG
影响因子:
3.1
作者:
Bowers, SG;Mahmud, T;Floss, HG
通讯作者:
Floss, HG
影响因子:
3.2
作者:
Minagawa, Kazuyuki;Zhang, Yirong;Mahmud, Taifo
通讯作者:
Mahmud, Taifo